Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 2916 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Evox Therapeutics–FTI Consulting: public relations, 202003 service existent by FTI Consulting 2020-03-26
SutroVax–Abingworth: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Abingworth 2020-03-26
SutroVax–Medicxi: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Medicxi 2020-03-26
SutroVax–SEVERAL: investment, 202003 financing round Series D $110m co-led by new investors RA Capital + Janus Henderson 2020-03-26
Takeda–Evox Therapeutics: exosome therapeutics, 202003– collab up to $926m + tiered royalties developm for up to 5 rare disease targets 2020-03-26
AstraZeneca–Silence Therapeutics: siRNA molecules, 202003– collab r+d strategic alliance $60m upfront + up to $400m for each disease target 2020-03-25
Silence Therapeutics–AstraZeneca: investment, 202003 equity investment $20m in connection with strategic siRNA alliance 2020-03-25
BMS–Oxford BioMedica: lentiviral vector technology, 202003– license non-excl + supply agreem LentiVector for CAR-T + TCR-T therapeutics of Juno 2020-03-18
Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS 2020-03-10
Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF 2020-03-10
Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical 2020-03-10
Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF 2020-03-10
Bone Therapeutics–Image Box: public relations, 202003– supply service by Image Box PR 2020-03-06
Autolus–MolMed: viral vectors, 202003– collab multi-year developm + supply of viral vectors by MolMed for T cell cancer therapies 2020-03-05
AstraZeneca–Voluntis: digital therapeutics, 202003 collab existent 2020-03-04
Evonetix–SEVERAL: investment, 202003 financing round Series B $30m (£23m) led by new investor Foresite Capital 2020-03-02
Immunocore–General Atlantic: investment, 202003 financing round Series B totalling $130m incl new + lead investor General Atlantic 2020-03-02
Immunocore–SEVERAL: investment, 202003 financing round Series B $130m led by new investor General Atlantic 2020-03-02
Sterling Pharma Solutions–Thermo Fisher: LC system, 202003 supply early customer for Vanquish Core HPLC System 2020-03-02
FinnGen–AstraZeneca: genomics, 202002 collab existent AstraZeneca is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–GSK: genomics, 202002 collab existent GSK is industry partner of Finnish genome research project FinnGen 2020-02-25
Roche–Bicycle Therapeutics: small-molecule drugs, 202002– collab strategic $30m upfront + up to $1.7b r+d of bicycle peptides for cancer Genentech 2020-02-25
GSK–Immatics: cell therapy, 202002– strategic collab $45m upfront + $1.1b milestones for first two TCR therapeutics programmes + royalties 2020-02-20
OMass–SEVERAL: investment, 202002 financing round Series A extension £27.5m bringing total Series A to £41.5m 2020-02-17
Pheno Therapeutics–SEVERAL: investment, 202002– financing round Series A £5m milestone-based over 3 years from Advent Life Sciences + SIB + LifeArc 2020-02-17
Pencil Biosciences–o2h: investment, 202002 investment by o2h Ventures Therapeutics and AI Fund 2020-02-15
Pencil Biosciences–United Kingdom (govt): grant, <202002 received Innovate UK grants 2020-02-15
Domainex–Sciad Communications: public relations, 202002 service existent by Sciad 2020-02-13
Inato–SEVERAL: investment, 202002 financing round Series A $14m led by Obious Ventures + Cathay Innovation 2020-02-04
Sumitomo–Exscientia: drug discovery, 202001 collab existent AI-based drug discovery using Centaur Chemist with Sumitomo Dainippon Pharma 2020-01-30
Stilla Technologies–Coulter Partners: recruitment services, 202001 supply service placement of Khaled Bahi as CFO at Stilla Technolgies 2020-01-28
Quench Bio–SEVERAL: investment, 202001 financing round Series A $50m led by RA Capital + incl AbbVie Ventures + Atlas Venture + Arix Bioscience 2020-01-27
iOnctura–SEVERAL: investment, 202001 financing round Series A €15m led by Inkef Capital + co-led by VI Partners 2020-01-23
Nanoform–Coulter Partners: recruitment services, 202001 supply service placement of Sally Langa as new head of US Sales at Nanoform 2020-01-21
Seekyo–Andrew Lloyd Associates: public relations, 202001 service existent by ALA 2020-01-20
Charles River–Fios Genomics: bioinformatics, 202001– collab providing Charles River’s customers access to Fios data analysis services 2020-01-16
Astellas–Adaptimmune: allogenic T-cell therapies, 202001– collab r+d CAR-T + TCR therapies with up to $897.5m for ADAP + up to $552.5m for Astellas 2020-01-14
Daiichi Sankyo–ERS Genomics: CRISPR technology, 202001– license ww excl €na for internal r+d 2020-01-13
Alderaan Biotechnology–SEVERAL: investment, 202001 financing round Series A €18.5m with Advent France Biotechnology + Medicxi 2020-01-09
Boehringer–PhoreMost: drug discovery services, 202001– collab €na multi-project target discovery using Siteseeker platform 2020-01-07
MiNA Therapeutics–Trophic Communications: public relations, 202001 service existent by Trophic Communications 2020-01-07
TherVacB project–EU (govt): grant, 202001–202412 Horizon 2020 grant €10.4m for development of therapeutic Hepatitis B vaccine 2020-01-01
Nabriva–Sam Brown: public relations, 201912 service existent by Sam Brown Inc 2019-12-20
Nabriva–SEVERAL: investment, 201912 registered direct offering $20m with 13.8m pairs ordinary share + warrant at $1.45/pair to institutional investors 2019-12-20
Pathios Therapeutics–SEVERAL: investment, 201912 financing round Series A $8.8m with Canaan + MRCF managed by Brandon Capital 2019-12-18
Edinburgh Molecular Imaging–SEVERAL: investment, 201912 financing round £3.1m from new investor Caribou Property + existing investors 2019-12-17
Flagship Pioneering–WPP: public relations, 201912 service existent by Ogilvy 2019-12-16
Start Codon–One Nucleus: business services, 201912– service support of start-ups participating in Start Codon accelerator programme by One Nucleus 2019-12-11
Charles River–Bit Bio: drug discovery technology, 201912– collab strategic excl discovery + safety services partnership reprograming of human cells 2019-12-10
Schauenburg–JP Scientific: SPE technology, 201912– ww commercial license + supply to Markes from JP Scientific Ltd 2019-12-10
Epidarex Capital–Zyme Communications: public relations, 201912 service existent by Zyme 2019-12-09
BC Platforms–Scius Communications: public relations, 201912 supply service existent by Scius Communications 2019-12-06
Jasper Therapeutics–Abingworth: investment, 201912 financing round Series A totalling $35m incl co-lead investor Abingworth 2019-12-06
Jasper Therapeutics–SEVERAL: investment, 201912 financing round Series A $35m led by Abingworth + Qiming Venture Partners USA 2019-12-06
Novartis–Oxford BioMedica: lentiviral vector technology, 201912– supply agreem extension for 5y 2019-12-01
ECBF–SEVERAL: investment, 201911– European Circular Bioeconomy Fund aims to raise €250m incl up to €100m from EIB 2019-11-29
Novo Group–Optimum Strategic Communications: public relations, 201911 service existent by Optimum 2019-11-26
Azeria Therapeutics–SEVERAL: investment, 201911 financing round Series B £32m led by Syncona with £29.5m plus investor CRT Pioneer Fund 2019-11-21
Azeria Therapeutics–Sixth Element Capital: investment, 201911 financing round Series B totalling £32m incl existing + co-investor CRT Pioneer Fund 2019-11-21
Azeria Therapeutics–Syncona: investment, 201911 financing round Series B totalling £32m incl £29.5m from new + lead investor Syncona 2019-11-21
GHO Capital–SEVERAL: investment, 201911 final closing of €975m GHO Capital Fund II LP 2019-11-20
Causaly–Copyright Clearance Center: Natural Language Processing s/w, 201911 collab existent to mine biomedical literature using AI 2019-11-19
Causaly–Sage Publishing: Natural Language Processing s/w, 201911 collab existent to mine biomedical literature using AI 2019-11-19
Causaly–SEVERAL: investment, 201911 financing round Series A $5m led by Pentech Ventures + incl EBRD VC + Marathon VC et al. 2019-11-19
Causaly–Wiley: Natural Language Processing s/w, 201911 collab existent to mine biomedical literature using AI 2019-11-19
Novartis–Causaly: Natural Language Processing s/w, 201911 collab existent 2019-11-19
Alkermes–WilmerHale: legal services, 201911 supply service WilmerHale legal advisor w regard to acquisition of Rodin by Alkermes 2019-11-18
Rodin Therapeutics–Alkermes: investment, 201911 acquisition $100m upfront cash + $850m milestones by Alkermes 2019-11-18
Rodin Therapeutics–Goodwin Procter: legal services, 201911 supply service Goodwin Procter legal advisor w regard to acquisition of Rodin by Alkermes 2019-11-18
Lunac Therapeutics–Epidarex Capital: investment, 201911 financing round Series A first closing totalling £2.65m incl co-lead investor Epidarex Capital 2019-11-14
Lunac Therapeutics–SEVERAL: investment, 201911 financing round Series A first closing £2.65m co-led by Epidarex Capital + Univ Leeds 2019-11-14
Lunac Therapeutics–Univ Leeds: investment, 201911 financing round Series A first closing totalling £2.65m incl co-lead investor Univ Leeds 2019-11-14
Turbine–Atlantic Labs: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Atlantic Labs Manager GmbH 2019-11-13
Turbine–Delin Ventures: investment, 201911 first institutional financing round totalling €3m incl lead investor Delin Ventures 2019-11-13
Turbine–o2h: investment, 201911 first institutional financing round totalling €3m incl new + co-investor o2h Ventures 2019-11-13
Turbine–PERSON: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Esther Dyson 2019-11-13
Turbine–PERSON: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Vishal Gulati 2019-11-13
Turbine–SEVERAL: investment, 201911 first institutional financing round €3m led by Delin Ventures + incl Atlantic Labs et al. 2019-11-13
Turbine–Zyme Communications: public relations, 201911 service existent by Zyme 2019-11-13
Expedeon–Abcam: investment, 201911– acquisition €120m cash of immunology + proteomics business of Expedeon by Abcam ANNOUNCED 2019-11-11
Aston Univ–Waters: mass spectrometer, 201911 supply first Select Series Cyclic IMS mass spectrometer installed at School of Health + Life Sciences 2019-11-07
Owlstone–Thermo Fisher: mass spectrometry, 201911– collab integration of Q Exactive GC Hybrid Quad-Orbitrap MS into Breath Biopsy platform 2019-11-07
Artios Pharma–Univ Texas: ATR inhibitors, 201911– license excl ww to small-molecula ATR inhibitor programme from MD Anderson + ShangPharma Innovation 2019-11-06
Ervaxx–Huntsworth: public relations, 201911 service existent by Citigate Dewe Rogerson 2019-11-06
Greenough–KDM Communications: investment, 201911 merger combination to provide transatlantic PR services 2019-11-06
OTHER–Ervaxx: cancer immunotherapy, 201911 collab existent strategic r+d partnership with undisclosed leading global pharma company 2019-11-06
Rentschler–General Electric: single-use bioreactor, 201911–202006 supply Xcellerex XDR-500 bioreactor for Rentschler facility in Milford, MA 2019-11-06
Urania Therapeutics–Andrew Lloyd Associates: public relations, 201911 service existent by ALA 2019-11-06
Pieris–BVF Partners: investment, 201911 private placement totalling $32m incl existing + lead investor BVF Partners 2019-11-04
Pieris–SEVERAL: investment, 201911 private placement $32m w 9.015m units (shares + warrants) at $3.55/unit led by BVF Partners 2019-11-04
AstraZeneca–BBG/Braun Group: quetiapine fumarate, 201910– acquisition $178m upfront + up to $61m rights to Seroquel/XR in Europe + RU by Cheplapharm 2019-10-30
Bavarian Nordic–GSK: vaccines, 201910 acquisition up to €796m incl €301m upfront of manufacturing + global rights to Rabipur/RabAvert + Encepur by BN 2019-10-21
Danaher–Sartorius: investment, 201910– acquisition $750m three life science businesses by Sartorius part of regulatory clearance for GE/Danaher deal 2019-10-21
Avacta–SEVERAL: investment, 201910– proposed placing + subscription up to £9m with 59.8m nrew ordinary shares at 15p/share 2019-10-18
Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund 2019-10-17
Adaptate Biotherapeutics–Abingworth: investment, 201910 investment by Abingworth + Takeda facilitating spin-out of Adaptate from GammaDelta Tx 2019-10-16
Adaptate Biotherapeutics–SEVERAL: investment, 201910 spin-out from GammaDelta Therapeutics with investment from Abingworth & Takeda Pharmaceutical 2019-10-16
Adaptate Biotherapeutics–Takeda: investment, 201910 investment by Abingworth + Takeda with time-limited option to acquire Adatpate for Takeda 2019-10-16
Healx–Amadeus Capital: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Amadeus Capital Partners 2019-10-16
Healx–Atomico: investment, 201910 financing round Series B totalling $56m incl new + lead investor Atomico 2019-10-16
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px

» top